Journal Article Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

Maruyama, Dai  ,  Nagai, Hirokazu  ,  Fukuhara, Noriko  ,  Kitano, Toshiyuki  ,  Ishikawa, Takayuki  ,  Shibayama, Hirohiko  ,  Choi, Ilseung  ,  Hatake, Kiyohiko  ,  Uchida, Toshiki  ,  Nishikori, Momoko  ,  Kinoshita, Tomohiro  ,  Matsuno, Yoshihiro  ,  Nishikawa, Tomoaki  ,  Takahara, Satoko  ,  Tobinai, Kensei

107 ( 12 )  , pp.1785 - 1790 , 2016-12 , Wiley-Blackwell
In this multicenter, single-arm, phase II study, the efficacy and safety of ibrutinib were examined in Japanese patients with relapsed or refractory mantle cell lymphoma (MCL). Patients (age ≥20 years) with relapsed or refractory MCL who had progressed after receiving at least one prior treatment regimen, were enrolled. Patients were treated with oral ibrutinib (560 mg once daily; 28-day cycle) until disease progression (or relapse), unacceptable toxicity, or study end. The primary end-point was overall response rate. Secondary end-points included duration of response (DOR), time to response, progression-free survival (PFS), overall survival, and safety. Of the 16 patients who received treatment, 5 patients discontinued the study (progressive disease, 4; sepsis, 1). Median duration of ibrutinib exposure was 6.5 months (range, 2.8–8.3 months). The overall response rate was 87.5% (90% confidence interval, 65.6–97.7; complete response = 2 [12.5%]; partial response = 12 [75.0%]). Median time to response for all responders (n = 14) was 1.8 months (range, 0.7–5.3 months). The median DOR and PFS were not estimable due to censoring (range: DOR, 1.1–6.4+ months; PFS, 2.8–8.0+ months). Overall survival data were immature due to the limited observation period. A total of 8/16 patients (50%) had at least one grade 3 adverse event (AE), and 5 (31.3%) patients reported serious AEs. The most commonly reported AEs were diarrhea and stomatitis (37.5% each), platelet count decrease (31.3%), and anemia (25%). Overall, orally administered single agent ibrutinib was efficacious with an acceptable safety profile in Japanese patients with relapsed or refractory MCL. Clinical trial registration NCT02169180 (

Number of accesses :  

Other information